Bullous pemphigoid (BP) is the most common type of subepidermal autoimmune bullous diseases, which characteristically affects the elderly and is seen mainly in patients older than 60. The disease is often misdiagnosed, and it takes an average of five visits to healthcare providers and approximately six months to obtain a correct diagnosis. No therapies are approved for BP in the United States. The corticosteroid prednisolone is authorized in some EU countries. In general, symptoms and disease progression are controlled by off-label corticosteroids (topical, systemic) in combination with immunomodulators / immunosuppressants, high-dose IVIG, and rituximab. The BP pipeline is crowded, with three molecules in advanced phases of clinical development (Phase III): AstraZeneca’s Fasenra SC (anti-IL-5), Sanofi / Regeneron’s Dupixent (anti-IL-4/IL-13), and Akari Therapeutics’ nomacopan (C5a + leukotriene B4 inhibitor). Three additional drugs are in Phase II development. Given the lack of approved therapies, unavailability of diagnostic biomarkers, and vulnerability of the patient population, the unmet needs and market opportunities for new therapies for BP are clear.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States, EU5
Primary research: 13 KOL interviews from November 2021 to January 2022
Key companies covered: AstraZeneca, Akari Therapeutics, Sanofi / Regeneron, Argenx, Alkahest, Innate Pharma
Key drugs covered: Fasenra, nomacopan, Dupixent, efgartigimod, AKST4290, avdoralimab